Exhibit 2.1 EXECUTION VERSION MEMBERSHIP UNIT PURCHASE AGREEMENT BY AND AMONG NEW AGE INVESTMENTS LLC, DERMADOCTOR, LLC, AND NOVABAY PHARMACEUTICALS, INC. March 12, 2024 Table of Contents Article 1 Definitions 1 Article 2 Membership Units to be Purchased 1 Article 3 Closing; Purchase Price; Closing Deliverables 1 Article 4 Representations and Warranties of DERMAdoctor 4 Article 5 Representations and Warranties of Seller 13 Article 6 Representations and Warranties of Buyer 15 Article 7 Covenants 16 Article 8 ...

财务数据和关键指标变化 - 第三季度总销售额为3.3亿美元,较上年同期3.8亿美元下降13% [30] - 第三季度毛利率为56%,较上年同期62%下降 [31] - 前9个月总销售额为11亿美元,较上年同期略有增长 [36] - 前9个月毛利率为55%,较上年同期56%略有下降 [36] - 截至9月30日,公司现金及现金等价物为3.5亿美元 [41] 各条业务线数据和关键指标变化 - 眼科业务Avenova产品销售额为2.4亿美元,占总销售额的72% [30] - 皮肤护理业务DERMAdoctor产品销售额为0.8亿美元,占总销售额的24% [30] - 伤口护理业务销售额为0.1亿美元,占总销售额的4% [30] 各个市场数据和关键指标变化 - 公司在中国的天猫双11销售活动是重点关注的销售渠道之一,预计将带来销售增长 [26][27] - 公司在美国的亚马逊渠道是最重要的销售渠道之一,公司利用亚马逊的Prime Day活动进行促销,取得了良好的销售业绩 [21] 公司战略和发展方向及行业竞争 - 公司将专注于销售最畅销的DERMAdoctor产品系列,通过数字营销提高销售效率 [23][24][45] - 公司推出新的Avenova Allograft产品,瞄准价值超过4亿美元的市场机会,并通过现有的眼科医生渠道进行推广 [15][17][18] - 公司将继续专注于提高运营效率,控制销售和营销费用,以延长现金流 [13][14][45] 管理层对经营环境和未来前景的评论 - 公司在医生推荐渠道的销售增长36%,体现了公司与眼科医生的良好关系 [11][12] - 公司在数字营销方面的专业能力帮助其降低销售和营销费用 [13][24] - 公司对中国双11销售活动和即将到来的节日销售旺季持乐观态度 [26][27] - 公司将继续专注于提高运营效率和现金管理,以应对当前的市场挑战 [14][45] 其他重要信息 - 公司的Avenova Spray和Avenova润滑眼药水产品未受到FDA关于某些进口眼药水的警告和召回的影响,继续正常销售 [22] - 公司在第三季度和前9个月的经营亏损分别为1.1亿美元和4.2亿美元,较上年同期有所改善 [32][37] 问答环节重要的提问和回答 问题1 **Destiny Buch 提问** 询问公司在DERMAdoctor业务方面的新策略以及第三季度收入下滑的原因 [48][49] **Justin Hall 回答** 公司今年将专注于在最有效的销售渠道销售最畅销的DERMAdoctor产品,而不是开发新产品。第三季度收入下滑主要是由于季节性因素和国际分销商订单的波动 [49][50][51] 问题2 **Destiny Buch 提问** 询问公司是否预计第四季度会有显著增长,以及医生推荐渠道的收入占比 [51][53][54] **Justin Hall 和 Tommy Law 回答** 公司预计第四季度中国双11销售活动和节日促销活动会带来收入增长。医生推荐渠道的收入占比约为50% [54][55] 问题3 **Destiny Buch 提问** 询问Avenova产品客户的生命周期价值以及Avenova Allograft产品的商业化策略 [57][62][63] **Justin Hall 回答** Avenova是公司最畅销的产品,20%的亚马逊销售来自订阅服务,体现了良好的客户粘性。Avenova Allograft是处方产品,公司主要通过眼科医生渠道进行销售,医生可以申请保险或Medicare报销 [57][58][59][63][64]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-045 ...

财务数据和关键指标变化 - 第二季度收入为4.6百万美元,同比增长26% [8] - 毛利率保持在50%,与上年同期持平 [26] - 总运营费用下降8%,其中销售和营销费用下降16% [27] - 经营亏损缩小37%至1.4百万美元 [28] - 上半年收入增长11%至7.7百万美元,毛利率提升至55% [29] - 上半年经营亏损下降32%至3.1百万美元 [29] - 2023年6月30日现金及等价物为4.4百万美元,包括5月份3百万美元可转换票据和认股权证的私募融资 [30] 各条业务线数据和关键指标变化 眼护理业务 - Avenova系列产品在医生渠道和亚马逊渠道均实现增长 [9][10][13] - Avenova系列产品在今年亚马逊Prime Day创下销售纪录,同比增长22%,环比增长43% [13][14] - 预计眼护理业务在剩余年度将实现增长,尤其是在线销售渠道 [15] 护肤品业务 - DERMAdoctor产品销售增长40%以上,其中中东和中国市场表现突出 [16] - 未来将聚焦于销售最畅销的4大产品系列,减少新产品开发投入以控制成本 [17][18][19][20][21] 创面护理业务 - 创面护理产品创下历史新高销售纪录,主要得益于中国合作伙伴的1百万美元订单 [22] - 美国合作伙伴PhaseOne Health的销售也有可观贡献,预计全年销售将超预期 [22] - 创面护理产品毛利率略低于其他业务,预计下半年整体毛利率将达到55%左右 [43] 公司战略和发展方向 - 聚焦于眼护理和创面护理业务的增长,护肤品业务则将集中于最畅销产品线的销售 [17][32] - 利用过去几年积累的数字营销专业知识,在控制成本的同时有效推广产品 [32] 管理层对经营环境和未来前景的评论 - 对眼护理业务的未来增长持乐观态度 [15] - 护肤品业务将通过聚焦最畅销产品线来实现盈利 [17] - 创面护理业务有望持续贡献可观收入,但大订单不会在每个季度重复出现 [39]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Jody Cain - LHA, IR Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Anderson Schock - Ladenburg Thalmann Operator Welcome to the NovaBay Pharmaceuticals First Quarter 2023 Financial Results Conference Call. At this time, all participants are in listen-only mode. Following management’s prepared remarks, we wil ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-33678 NOVABAY PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 68-0454536 (Sta ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Jody Cain - Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Welcome to the NovaBay Pharmaceuticals??? 2022 Fourth Quarter and Full Year Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. ...

NovaBay Pharmaceuticals, Inc. (NYSE:NBY) DERMAdoctor Acquisition Conference Call September 29, 2021 4:30 PM ET Company Participants Jody Cain - SVP, LHA, IR Justin Hall - CEO Audrey Kunin - DERMAdoctor, Co-Founder and Chief Product Officer Jeffrey Kunin - DERMAdoctor President, CEO and Co-Founder Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann & Co. Inc. Edward Woo - Ascendiant Capital Markets, LLC Operator Welcome to the NovaBay Pharmaceuticals and DERMAdoctor Acquisition Conference Call. A ...